Study of a new drug combination for advanced Hodgkin lymphoma with HIV
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment combination for people with advanced Hodgkin lymphoma who also have HIV. The goal is to see if this approach is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of classical Hodgkin lymphoma that is advanced (stage IIB, III, or IV).
- You must have HIV, with a CD4 count of at least 150 at the time of joining, or at least 250 at some point in the 8 months before your lymphoma diagnosis.
- You must be either already on HIV treatment (ART) or willing to start it.
- You must be between 18 and 60 years old.
- You must not have had another cancer in the last 5 years (except some types that don't count), and you must not have had prior chemotherapy or radiation that would interfere with this trial.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has not responded to treatment or has returned. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy drug called an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to at least two previous treatments. It may be an option if you cannot have or do not want a stem cell transplant.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Hear when a new Hodgkin Lymphoma (Category) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.